M. Reynolds

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: a multicentre, open-label, phase 1 study

Jessica L. Davis, B. Tuch, A. Pappo, 2018 .

A phase II basket study of the oral TRK inhibitor LOXO–101 in adult subjects with NTRK fusion-positive tumors

A. Drilon, D. Hyman, D. Hong, 2016 .

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Jessica L. Davis, B. Tuch, A. Pappo, 2018, The Lancet. Oncology.

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

Jessica L. Davis, A. Pappo, D. Hawkins, 2018, Cancer.

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma

M. Cowley, M. Pinese, P. Ekert, 2018, British Journal of Cancer.

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion

S. Bielack, C. Blattmann, M. Nathrath, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma

A. Pappo, M. Neel, M. B. McCarville, 2018, Pediatric blood & cancer.

A pediatric phase 1 study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.

A. Pappo, Steven G. Smith, T. Laetsch, 2016 .